Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.

Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

Biotechnology

Eidos Therapeutics

Neil Kumar

Suresh Siddhanti

Stuart Heminway

Satish Rao

Mamoun Alhamadsheh

Leonid K.

Jonathan Cascon

Janet Hsu

Isabella Graef

Ananth Sridhar

Jonathan Fox

Matt Outten

Uma Sinha

The founding team at Eidos Therapeutics has a history of experience in both academia and industry. The team includes members with a range of experience, from an assistant professor at Stanford University to those with experience in the biotech industry. The team also has a range of educational backgrounds, from a microbioligist and immunologist to someone with a degree in business.

Founding Team

Leadership Team

CEO and Executive Team

Board of Directors

Founding Team

About

Team members

Other teams at Eidos Therapeutics

Leadership Team

CEO and Executive Team

Board of Directors